Denosumab delays the time to first skeletal-related event in patients with myeloma
53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago – According to Phase 3 ‘482 study, the largest international multiple myeloma trial ever conducted with 1,718 patients involved, patients who receive denosumab…